AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02969057 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast with rice bran oil
Description: 25 grams of rice bran oil
Study NCT02969057 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast with palm oil gel
Description: 25 grams of palm oil gel
Study NCT02969057 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast with palm oil
Description: 25 grams of palm oil
Study NCT04349423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Usage Manipulation
Description: Behavioral Intervention of social media usage.
Study NCT01049035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate
Description: 0.5 milliliter (mL), Intramuscular (IM) injection
Study NCT01049035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined)
Description: 0.5 mL, IM injection
Study NCT01049035 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined)
Description: 0.5 mL, IM injection
Study NCT01049035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live
Description: 0.5 mL, Subcutaneous (SC) injection
Study NCT01049035 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live
Description: 0.5 mL, Subcutaneous (SC) injection
Study NCT01049035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Virus Vaccine Live
Description: 0.5 mL, SC injection
Study NCT01049035 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Varicella Virus Vaccine Live
Description: 0.5 mL, SC injection
Study NCT01049035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)
Description: 0.5 mL, IM injection
Study NCT01049035 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)
Description: 0.5 mL, IM injection
Study NCT01049035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)
Description: 0.5 mL, IM injection
Study NCT01457053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loop diuretics (furosemide, torsemide, bumetanide)
Description: Patients with ADHF and hypervolemia will be enrolled in a prospective, randomized fashion.~Subjects will be randomized with a computer generated random number function to either ultrafiltration or diuretic therapy within 24 hours of hospitalization for the management of fluid overload.~Patients randomized to diuretic therapy will be treated with intravenous loop diuretics (e.g. furosemide, bumetanide, torsemide). The selection of diuretic, dose and frequency of diuretic administration will be determined by the treating physicians based upon clinical assessment of volume status, response to medication, and perceived safety.
Study NCT01457053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrafiltration
Description: Subjects will be randomized with a computer generated random number function to either ultrafiltration or diuretic therapy within 24 hours of hospitalization or outpatient heart failure clinic for the management of fluid overload. If randomized to the ultrafiltration arm, on admission to the hospital patients will be initiated on ultrafiltration therapy for 2-5 days.~Patients randomized to UF will be treated using the Aquadex System 100 ultrafiltration device (CHF Solutions, Minneapolis, MN). The selection of ultrafiltration rate (fluid removal rate)will be determined by the treating physicians based upon clinical assessment of volume status and perceived safety.
Study NCT00077948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoximone
Description: Enoximone administered orally
Study NCT00077948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol succinate
Description: Metoprolol succinate administered orally
Study NCT00077948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate
Description: Metoprolol succinate administered orally
Study NCT00077948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match enoximone
Description: Placebo to match match enoximone administered orally
Study NCT00077948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match enoximone
Description: Placebo to match match enoximone administered orally
Study NCT00077948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match metoprolol succinate
Description: Placebo to match metoprolol succinate administered orally
Study NCT03827863 — intervention group
Intervention type: DEVICE
Intervention: TTE
Description: TTE to detect the heart function
Study NCT01049035 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)
Description: 0.5 mL, IM injection
Study NCT01049035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine
Description: oral
Study NCT01049035 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Rotavirus Vaccine
Description: oral
Study NCT01049035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine
Description: 0.5 mL, IM injection
Study NCT01049035 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hepatitis B Vaccine
Description: 0.5 mL, IM injection
Study NCT01891487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Track A
Description: Bimatoprost 0.03% solution applied to eyebrow
Study NCT01891487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Track B
Description: Refresh Tears applied to eyebrows
Study NCT04255056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib is administered orally at 400 mg daily from day 1 of the first cycle to day 21 of the fourth cycle or to the day of surgery, within 30 minutes after breakfast.~Epirubicin (90 mg/m2), intravenously, every 21 days. Cyclophosphamide (600 mg/m2), intravenously, every 21 days.
Study NCT03548051 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: 100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema
Study NCT03548051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 250 ml of saline delivered by retention enema
Study NCT00529256 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Feeback group
Description: The intervention practices received a quarterly comparative feedback performance report based on the Achievable Benchmarks of Care (ABC) research conducted by Kieffe (YEAR).
Study NCT03402607 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Local Ablation
Description: Microwave Ablation (MWA) is a form of percutaneous localized ablation using thermal ablation techniques to treat cancer via direct coagulative necrosis. Microwaves can generate high temperatures in a short period of time; MWA has the potential to improve treatment efficacy over radiofrequency ablation as it can be used to treat larger lesions and has less susceptibility to heat-sink due to vessel proximity. MWA uses electromagnetic waves (300 MHz to 300 GHz) to produce oscillation of polar molecules within tissue; this generates tissue necrosis through frictional heating. For HCC, one or more microwave antennae are inserted into the liver, usually under the guidance of ultrasonography or computed tomography (CT). Frequency and length of treatment is determined on a case by case basis depending on tumor size and proximity to vessels or other organs at risk.
Study NCT03402607 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated Image Guided Radiation Therapy
Description: HIGRT represents the only non-invasive curative modality in the management of HCC. HCC patients typically have a host of other medical comorbidities complicated by underlying liver dysfunction that makes the implementation of liver-directed therapy challenging. Presently HIGRT is typically offered only after alternative surgical (transplantation/hepatectomy) and non-operative approaches (PLA/embolization) have been exhausted.
Study NCT03766880 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transjugular HVPG measurement
Description: By means of catheterization of a hepatic vein with a balloon catheter.
Study NCT03766880 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR imaging
Description: MR images for the post-processing analysis
Study NCT00488891 — intervention group
Intervention type: DRUG
Intervention: Paliperidone ER
Description: Route = oral. Paliperidone ER will be prescribed to the patients at the investigator's discretion. Patient receive their medication according to usual care in their treatment setting ie, no study drug is provided
Study NCT00488891 — intervention group
Intervention type: DRUG
Intervention: Atypical antipsychotics (AAP)
Description: Route = oral. AAP including quetiapine, risperidone, olanzapine, ziprasidone or aripiprazole. Dosage and administration of antipsychotics will be prescribed at the investigator's discretion
Study NCT03874377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness refers to the experience of paying attention to the present moment in a nonjudgmental manner. The mindfulness intervention consists of 6 weekly sessions focused on: experiential mindfulness exercises, such as mindful eating, loving kindness practices, breath awareness, and mindful movement; hunger and satiety awareness; improving responses to emotions; practicing acceptance and being non-judgmental; and tolerating negative feelings and sensations, including those related to hunger and cravings. Participants will be assigned brief homework exercises (approximately 10 minutes) daily in between appointments.
Study NCT03874377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will receive the recommended standard of medical management of overweight and obesity. The clinic team conducts a comprehensive evaluation of the patient to assess dietary and activity behavior change needs of each patient and family, as well as obesity-associated comorbidities. In addition to management of comorbidities, goals for improved physical activity and dietary behaviors are set with the patient and family at each visit.
Study NCT01768455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin and Glimepiride
Description: Gemigliptin 50mg (qd) on Day1\~Day6 and Gemigliptin 50mg (qd) and Glimepiride 4mg (qd) on Day7
Study NCT01768455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glimepiride 4mg (qd) on Day1
Study NCT02896595 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia with endotracheal tube
Description: Patient randomized to this arm will have general anesthesia with endotracheal tube placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.
Study NCT02896595 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia with laryngeal mask airway
Description: Patients randomized to this arm will have general anesthesia with laryngeal mask airway placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.
Study NCT03206697 — intervention group
Intervention type: OTHER
Intervention: Mitochondrial DNA content and metabolic parameters
Description: Analyze the correlation between the mitochondrial DNA content and metabolic parameters.
Study NCT02564315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Mini-Lozenge for 11 Months
Description: Participants receive up to 11 months of Nicotine Mini-Lozenges as part of this treatment (dosing based on their nicotine dependence as measured when they started the study: 4 mg if they smoked within 30 minutes of waking and 2 mg if they smoked more than 30 minutes after waking, as per the package insert), along with instructions for use.
Study NCT02564315 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preparation Phase Behavioral Reduction Counseling
Description: Participants randomized to receive this treatment receive manual-based counseling calls and visits over the course of 11 months. The ultimate goal will be smoking that is reduced in amount and location. Case managers and participants will collaboratively identify a set of steps to progressively reduce smoking. The primary vehicles for change are to encourage substitution of the nicotine mini-lozenge for cigarettes and to reduce the contexts in which smoking occurs. Counseling will counter post-lapse demoralization by emphasizing participants' progress, the value of smoking reduction as a transitional goal, and the critical value of ongoing treatment engagement. Evidence of progress in reduction of smoking, and smoking contexts will be used to build self-efficacy.
Study NCT02564315 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preparation Phase Recycling Counseling
Description: Participants randomized to receive this treatment condition will be encouraged to commit to a new quit date as soon as they feel ready. In the counseling sessions, participants will be encouraged to discuss reasons for and concerns about quitting as well as barriers to setting a quit date.
Study NCT02564315 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Preparation Phase Control Treatment
Description: Participants randomly assigned to the Preparation Phase Control Treatment condition will continue to receive the Initial Cessation usual care treatment (8 weeks of nicotine patch; two coaching sessions), but will also be told that they can receive additional treatment at no cost from the Wisconsin Tobacco Quitline (WTQL).
Study NCT02564315 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cessation Phase Supportive Counseling
Description: Supportive Counseling will be consistent with the Public Health Service (PHS) Clinical Practice Guideline (Fiore et al., 2008) and will involve encouragement, a focus on short-term goals, discussion of participant values (what the participant feels would be good and healthy for them in the long run) and how these values are congruent with cessation, emphasis on the patient and the counselor being a team, encouragement for the participant to generate a quitting strategy with the message that smokers often have a good sense of what will work for them, and prompts for the participant to explore his/her feelings about quitting and feelings of optimism and concern (i.e., to use the counselor as a sounding board).
Study NCT02564315 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cessation Phase Skill Training Counseling
Description: Skill training Counseling will: 1) carefully assess smoking cue contexts and opportunities to smoke, to identify problems encountered in the prior quit attempt; 2) develop specific plans for avoiding such contexts and identify skills for coping with them; 3) develop plans for negotiating with others who smoke; 4) develop lifestyle changes to reduce future smoking opportunities and contexts; and 5) assign homework and assess execution of assigned skills. Participants will receive coping menus that provide personalized coping/avoidance options and coping reports that assess coping execution over time and troublesome contexts and cues around which counseling will be focused. There will be praise for any progress and a collaborative determination of barriers to skill execution.
Study NCT02564315 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cessation Phase Brief Information
Description: Participants randomized to receive Brief Information will receive brief (generic) information about the importance of taking the cessation medication, how to use the medication, information about side effects/safety, and what to do in case of problems, and will also be given encouragement to quit smoking.
Study NCT02564315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge
Description: All participants will receive 8-weeks of combination NRT (nicotine patch + nicotine mini-lozenge). Nicotine patch dosing will be based on current cigarettes smoked per day, per package insert: for those who currently smoke >10 cigs/day=4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches, along with nicotine mini-lozenges; for those who currently smoke \<=10 cigs/day=6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches along with mini-lozenges. Mini-lozenge dosing will be based on how soon participants currently smoke after waking before their initial quit attempt and will be consistent with the package insert (4 mg for participants who smoke within 30 minutes of waking and 2 mg for participants smoke more than 30 minutes after waking).
Study NCT04187885 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group/Cohort 2: PAP
Description: Each experimental session will be carried out over 5 days of a week. Adolescents will take part randomly in four sessions.~Physical activity program will be identical between sessions and groups. 60 min of moderate to vigorous leisure activities and exercises will be proposed each day. Heart rate monitor will be used to control intensity of exercise during the physical activity program.
Study NCT04187885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group/Cohort 2: PAP
Description: Each experimental session will be carried out over 5 days of a week. Adolescents will take part randomly in four sessions.~Physical activity program will be identical between sessions and groups. 60 min of moderate to vigorous leisure activities and exercises will be proposed each day. Heart rate monitor will be used to control intensity of exercise during the physical activity program.
Study NCT01871454 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic ablative radiotherapy (SABR)
Description: standard of care radiation therapy
Study NCT01871454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: pentoxifylline
Study NCT04193917 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Conjunctival swab
Description: A conjunctival swab of both eyes will be taken at the same time together with an extensive questionnaire.
Study NCT00590590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine/Diphenhydramine
Description: semi solid, twice weekly, 4 months
Study NCT00590590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: semi solid, twice weekly for 4 months
Study NCT00590590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: semi solid, twice weekly for 4 months
Study NCT00595712 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Iliac crest allograft
Description: Opening wedge osteotomy of proximal tibia with allograft from iliac crest
Study NCT00595712 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Iliac crest autograft
Description: open wedge osteotomy of proximal tibia using autogenous iliac bone graft
Study NCT04421274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells transfer
Description: Inject the BM-MSCs into the infarct-related arterial hypertension through the central cavity of the guide wire balloon catheter under the complete blockage of the target blood vessel. Each time the balloon continues to fill for 2 minutes to block blood flow, then resume perfusion for 2 minutes. The above process is repeated 6 \~ 8 times
Study NCT04421274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best medical treatment
Description: Refer to the latest medication guidelines and give the best medication to the patients
Study NCT04421274 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Best medical treatment
Description: Refer to the latest medication guidelines and give the best medication to the patients
Study NCT04421274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention
Study NCT01006629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: palivizumab
Description: palivizumab 15 mg/kg intramuscularly
Study NCT00627107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReWalk - a motorized exoskeleton suit
Description: The subject will wear the ReWalk suit and have training sessions for walking with the device.
Study NCT02127853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Description: 100 mg tid of gabapentin is prescribed to the patient for 1 week after the first eye surgery
Study NCT02127853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the same regimen of placebo drug is prescribed to the patient for 1 week after the first eye surgery
Study NCT04563325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral co-amoxiclav or oral dicloxacillin only
Description: High dose oral treatment followed by standard dose oral treatment
Study NCT04563325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV ceftriaxon followed by oral co-amoxiclav or oral dicloxacillin
Description: IV treatment followed by standard dose oral treatment
Study NCT04135534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group A
Description: mutonpain 0.05 mg/kg